Publication

The therapeutic role of NAD+ modulation in fatty liver disease

Publications associées (54)

Graph Chatbot

Chattez avec Graph Search

Posez n’importe quelle question sur les cours, conférences, exercices, recherches, actualités, etc. de l’EPFL ou essayez les exemples de questions ci-dessous.

AVERTISSEMENT : Le chatbot Graph n'est pas programmé pour fournir des réponses explicites ou catégoriques à vos questions. Il transforme plutôt vos questions en demandes API qui sont distribuées aux différents services informatiques officiellement administrés par l'EPFL. Son but est uniquement de collecter et de recommander des références pertinentes à des contenus que vous pouvez explorer pour vous aider à répondre à vos questions.

Connectez-vous pour utiliser Chat avec Graph Search

Longitudinal osmotic and neurometabolic changes in young rats with chronic cholestatic liver disease

Cristina Ramona Cudalbu, Veronika Rackayová

Type C hepatic encephalopathy (type C HE) is increasingly suspected in children with chronic liver disease (CLD), and believed to underlie long-term neurocognitive difficulties. The molecular underpinnings of type C HE in both adults and children are incom ...

2020

, , , ,

The invention provides a method for obtaining a three-dimensional (3D) cellular model of tissue fibrosis, such as liver fibrosis, comprising culturing epithelial cells in a 3D hydrogel in conditions suitable for a three-dimensional cellular cluster formati ...

2020

Investigating the deregulation of metabolic tasks via Minimum Network Enrichment Analysis (MiNEA) as applied to nonalcoholic fatty liver disease using mouse and human omics data

Vassily Hatzimanikatis, Vikash Kumar Pandey

Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic syndromes spanning a wide spectrum of diseases, from simple steatosis to the more complex nonalcoholic steatohepatitis. To identify the deregulation that occurs in metabolic processes at ...

2019

The liver has a complex and unique microenvironment with multiple cell-cell interactions and internal vascular networks. Although nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with multiple phases, no proper model could ...

2019

A Human Liver-on-a-Chip Platform for Modeling Nonalcoholic Fatty Liver Disease

Soufian Lasli

The liver possesses a unique microenvironment with a complex internal vascular system and cell-cell interactions. Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease, and although much effort has been dedicated to buil ...

2019

, , , , , ,

To-date, most proteomic studies aimed at discovering tissue-based cancer biomarkers have compared the quantity of selected proteins between case and control groups. However, proteins generally function in association with other proteins to form modules loc ...

2019

Selective autophagy ensures the removal of specific soluble proteins, protein aggregates, damaged mitochondria, and invasive bacteria from cells. Defective autophagy has been directly linked to metabolic disorders. However how selective autophagy regulates ...

Springer2019

The cost-effectiveness and value of additional information about a health technology or program may change over time because of trends affecting patient cohorts and/or the intervention. Delaying information collection even for parameters that do not change ...

2018

The invention relates to plasma or liver lipid species selected from the triacylglycerol (TAG) and cardiolipin (CL) lipid classes measured by LC-MS/MS and use thereof as diagnostic and prognostic biomarkers of fatty liver, as well as to monitor the efficac ...

2018

Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease

Johan Auwerx, Kristina Schoonjans, Alessia Perino, Vera Monica Lemos Da Silva, Jun Yong Kim, Dongryeol Ryu, Elena Katsyuba, Hongbo Zhang, Keir Joe Menzies, Matthias Alexander Sokrates Stein, Karim Laurent Gariani, Pooja Jha

Background & Aims: To date, no pharmacological therapy has been approved for non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the therapeutic potential of poly ADP-ribose polymerase (PARP) inhibitors in mouse models o ...

Elsevier Science Bv2017